| scholarly article | Q13442814 |
| P2093 | author name string | H Gilbert Welch | |
| Archie Bleyer | |||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mammography | Q324634 |
| P304 | page(s) | 1998-2005 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Effect of three decades of screening mammography on breast-cancer incidence | |
| P478 | volume | 367 |
| Q34745051 | 3D parallel-detection microwave tomography for clinical breast imaging |
| Q61810504 | 3D-printed breast phantom for multi-purpose and multi-modality imaging |
| Q47127845 | A Laser-Activated Biocompatible Theranostic Nanoagent for Targeted Multimodal Imaging and Photothermal Therapy |
| Q92383927 | A Validation Study of a Multiple Reaction Monitoring-Based Proteomic Assay to Diagnose Breast Cancer |
| Q40420399 | A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer |
| Q36730143 | A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice--the ProCaRis study: study protocol |
| Q33763855 | A comparison of the risks of in-breast recurrence after a diagnosis of dcis or early invasive breast cancer |
| Q30415161 | A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women |
| Q36044136 | A multi-wavelength, laser-based optical spectroscopy device for breast density and breast cancer risk pre-screening |
| Q35102556 | A reality check for overdiagnosis estimates associated with breast cancer screening |
| Q38203301 | A review of clinical aspects of breast cancer |
| Q39087791 | Accuracy is in the eyes of the pathologist: The visual interpretive process and diagnostic accuracy with digital whole slide images |
| Q35067706 | Addressing overdiagnosis and overtreatment in cancer: a prescription for change |
| Q34079901 | Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines |
| Q35028200 | An analysis of mass screening strategies using a mathematical model: comparison of breast cancer screening in Japan and the United States |
| Q38418876 | An open letter to panels that are deciding guidelines for breast cancer screening |
| Q35874123 | An update in breast cancer screening and management. |
| Q37178877 | Analysis of motion during the breast clamping phase of mammography |
| Q52606246 | Analysis of utilization patterns and associated costs of the breast imaging and diagnostic procedures after screening mammography. |
| Q30768230 | Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time? |
| Q41354567 | Applying under-sampling techniques and cost-sensitive learning methods on risk assessment of breast cancer |
| Q47134716 | Approach to breast cancer early detection via tracking of secondary speckle patterns reflected from the skin with artificial intradermal impurity. |
| Q37589049 | Arguments against mammography screening continue to be based on faulty science |
| Q90441598 | Assessing trends of breast cancer and carcinoma in situ to monitor screening policies in developing settings |
| Q39728241 | Association between Breast Parenchymal Complexity and False-Positive Recall From Digital Mammography Versus Breast Tomosynthesis: Preliminary Investigation in the ACRIN PA 4006 Trial |
| Q35572286 | Association between apple consumption and physician visits: appealing the conventional wisdom that an apple a day keeps the doctor away |
| Q57109579 | Autoantibodies as Potential Biomarkers in Breast Cancer |
| Q36193581 | Autoantibody Response to ZRF1 and KRR1 SEREX Antigens in Patients with Breast Tumors of Different Histological Types and Grades. |
| Q94465940 | BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression |
| Q35555984 | Benefits and harms of mammography screening |
| Q36770273 | Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis |
| Q49956327 | Benefits, harms and evidence - reflections from UK primary healthcare. |
| Q42380799 | Bilateral Image Subtraction and Multivariate Models for the Automated Triaging of Screening Mammograms. |
| Q40042602 | Biology and etiology of young-onset breast cancers among premenopausal African American women: results from the AMBER Consortium |
| Q37591506 | Biomarkers of Helicobacter pylori-associated gastric cancer. |
| Q50051852 | Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer. |
| Q30392491 | Breast Biopsy: The Effects of Hypnosis and Music |
| Q89781949 | Breast Cancer Detection-A Synopsis of Conventional Modalities and the Potential Role of Microwave Imaging |
| Q36452235 | Breast Cancer Prevention: Can Women's Expectations Be Met? |
| Q27347760 | Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society |
| Q90607597 | Breast Cancer Screening: a Paradigm Change Is Needed-the PB Desai Oration |
| Q37017024 | Breast Cancer in Sub-Saharan Africa: Challenges and Opportunities to Reduce Mortality |
| Q36051600 | Breast Cancer-Specific Mortality Pattern and Its Changing Feature According to Estrogen Receptor Status in Two Time Periods |
| Q39187548 | Breast Density Notification Legislation and Breast Cancer Stage at Diagnosis: Early Evidence from the SEER Registry |
| Q37150630 | Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina Breast Cancer Study: a case-control study |
| Q38221967 | Breast cancer classification: linking molecular mechanisms to disease prognosis |
| Q91444115 | Breast cancer deaths averted over 3 decades |
| Q57107513 | Breast cancer in adolescents and young adults |
| Q35564427 | Breast cancer in ethnically different populations |
| Q51323974 | Breast cancer incidence: Decreasing trend in large tumours in women aged 50-74. |
| Q41382880 | Breast cancer screening in Austria: Key figures, age limits, screening intervals and evidence |
| Q35125812 | Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. |
| Q28081267 | Breast cancer screening: an evidence-based update |
| Q38967479 | Breast cancer screening: past, present and future |
| Q38082665 | Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries |
| Q41120364 | Breast cancer: The importance of overdiagnosis in breast-cancer screening |
| Q45352815 | Breast cancer: an increasing public health problem in the Asia Pacific region |
| Q36699168 | Breast carcinoma detection modes and death in a female population in relation to population-based mammography screening. |
| Q38382288 | Breast density: the trend in breast cancer screening |
| Q44084749 | Breast screening: an obsessive compulsive disorder |
| Q55249612 | Burden of early, advanced and metastatic breast cancer in The Netherlands. |
| Q37538384 | CAGS and ACS evidence based reviews in surgery. 48. What is the effect of screening mammography on breast cancer incidence? |
| Q35929665 | CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis |
| Q55329422 | Can Health Belief Model Predict Breast Cancer Screening Behaviors? |
| Q38254913 | Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers? |
| Q38668005 | Cancer Screening in the Elderly: A Review of Breast, Colorectal, Lung, and Prostate Cancer Screening |
| Q26864419 | Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening |
| Q27001043 | Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening |
| Q41929587 | Cancer screening in women living with HIV infection |
| Q55298639 | Cancer screening recommendations: an international comparison of high income countries. |
| Q34771560 | Cancer survivors in Switzerland: a rapidly growing population to care for. |
| Q40595247 | Cause-specific mortality in women with breast cancer in situ |
| Q59809876 | Cell Origins of High-Grade Serous Ovarian Cancer |
| Q35541390 | Cell-lineage heterogeneity and driver mutation recurrence in pre-invasive breast neoplasia |
| Q34023713 | Challenges to the early diagnosis and treatment of breast cancer in developing countries |
| Q35221291 | Changes in breast cancer risk distribution among Vermont women using screening mammography |
| Q64271286 | Changing Paradigms in Breast Cancer Screening: Abbreviated Breast MRI |
| Q36905676 | Circulating microRNA-based screening tool for breast cancer |
| Q64052205 | Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg |
| Q57473419 | Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients |
| Q45814350 | Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program. |
| Q38122442 | Complications and morbidity following breast reconstruction--a review of 16,063 cases from the 2005-2010 NSQIP datasets. |
| Q37096178 | Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies |
| Q39181696 | Construction of breast cancer gene regulatory networks and drug target optimization |
| Q88208858 | Contrast-enhanced cone-beam breast-CT (CBBCT): clinical performance compared to mammography and MRI |
| Q38211424 | Controversies in breast cancer screening for women aged 40-49 years |
| Q38273368 | Controversies surrounding screening mammography. |
| Q53563765 | Cost-effectiveness and sustainability of breast cancer screening and new anti-cancer drugs. |
| Q64124207 | Cost-effectiveness of breast cancer screening in the National Breast and Cervical Cancer Early Detection Program |
| Q47151834 | Cryoablation of Primary Breast Cancer in Patients with Metastatic Disease: Considerations Arising from a Single-Centre Data Analysis |
| Q41698507 | Current and Future Methods for Measuring Breast Density: A Brief Comparative Review |
| Q92222370 | Current and future trends in photoacoustic breast imaging |
| Q38685947 | Current approach and future perspective for ductal carcinoma in situ of the breast |
| Q87822676 | Current controversies in screening mammography |
| Q87449831 | DCIS and invasive interval breast cancer |
| Q35434433 | DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer |
| Q46231607 | Decision-Making Regarding Mammography Screening for Older Women |
| Q46644058 | Delayed breast cancer presentation: hospital data should inform proactive primary care. |
| Q52935837 | Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients. |
| Q37278390 | Delivering high-quality and affordable care throughout the cancer care continuum |
| Q41117152 | Depression, Antidepressant Use, and Postmenopausal Breast Cancer Risk |
| Q33596111 | Development and evaluation of a decision aid on mammography screening for women 75 years and older |
| Q57804321 | Development of an eHealth System to Capture and Analyze Patient Sensor and Self-Report Data: Mixed-Methods Assessment of Potential Applications to Improve Cancer Care Delivery |
| Q35531877 | Diagnostic and therapeutic path of breast cancer: effectiveness, appropriateness, and costs--results from the DOCMa study |
| Q35893019 | Diagnostic concordance among pathologists interpreting breast biopsy specimens |
| Q34014487 | Dietary fat intake in relation to lethal breast cancer in two large prospective cohort studies |
| Q38618874 | Disparities in Breast Cancer: Private Patients Have Better Outcomes Than Public Patients. |
| Q64262942 | Do doctors who order more routine medical tests diagnose more cancers? A population-based study from Ontario Canada |
| Q58799732 | Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer |
| Q91936366 | Downstaging in opportunistic breast cancer screening in Brazil: a temporal trend analysis |
| Q38696796 | Ductal carcinoma in situ - update on risk assessment and management |
| Q91559534 | Ductal carcinoma in situ of the breast: an update for the pathologist in the era of individualized risk assessment and tailored therapies |
| Q92377712 | Ductal carcinoma in situ of the breast: immune cell composition according to subtype |
| Q91723932 | Ductal carcinoma in situ: to treat or not to treat, that is the question |
| Q90742700 | Effect of Consultation on Adherence to Clinical Breast Examination and Mammography in Iranian Women: A Randomized Control Trial |
| Q34181432 | Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study |
| Q55209578 | Effect of mammography screening on stage at breast cancer diagnosis: results from the Korea National Cancer Screening Program. |
| Q36662053 | Effect of organised mammography screening on stage-specific incidence in Norway: population study. |
| Q33895457 | Effect of payment incentives on cancer screening in Ontario primary care |
| Q92076018 | Effect of screening mammography on breast cancer mortality: Quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort |
| Q41075279 | Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007. |
| Q39346419 | Effects of breast density and compression on normal breast tissue hemodynamics through breast tomosynthesis guided near-infrared spectral tomography. |
| Q34736052 | Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality |
| Q48075339 | Electrical nanowell diagnostics sensors for rapid and ultrasensitive detection of prostate-specific antigen |
| Q42555870 | Electronic health records and ambulatory quality |
| Q46932137 | Emerging Trends in Family History of Breast Cancer and Associated Risk |
| Q38216322 | Endocrine aspects of bone metastases |
| Q26861387 | Enhancing cancer care in areas of limited resources: our next steps |
| Q35396439 | Epidemics avoidable and unavoidable |
| Q37725545 | Epidemiology and survival outcome of breast cancer in a nationwide study. |
| Q38968841 | Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer. |
| Q89457572 | Establishment and validation of an immunodiagnostic model for prediction of breast cancer |
| Q40436516 | Estimating the Accuracy Level Among Individual Detections in Clustered Microcalcifications |
| Q48104203 | Estimating the frequency of indolent breast cancer in screening trials |
| Q50673917 | Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. |
| Q37398276 | Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme |
| Q27300398 | Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States. |
| Q35840714 | Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer |
| Q37641214 | Evaluation issues in the Swedish Two-County Trial of breast cancer screening: An historical review |
| Q34810319 | Evaluation of the Quality of Life in Adult Cancer Survivors (QLACS) scale for early post-treatment breast cancer survivors |
| Q30606545 | Existing data sources for clinical epidemiology: the Danish Quality Database of Mammography Screening |
| Q44248153 | Explaining variations in breast cancer screening across European countries |
| Q41490979 | Facility Mammography Volume in Relation to Breast Cancer Screening Outcomes |
| Q38682307 | Factors Associated With Underestimation of Invasive Cancer in Patients With Ductal Carcinoma In Situ: Precautions for Active Surveillance |
| Q33738451 | Feasibility of preoperative (125)I seed-guided tumoural tracer injection using freehand SPECT for sentinel lymph node mapping in non-palpable breast cancer |
| Q35859450 | Fine needle aspiration cytology of lymph nodes in breast cancer follow-up is a feasible alternative to watchful waiting and to histology |
| Q85660134 | Flawed assumptions used to defend screening mammography |
| Q26779927 | Four Principles to Consider Before Advising Women on Screening Mammography |
| Q35757874 | Framing overdiagnosis in breast screening: a qualitative study with Australian experts |
| Q35694177 | From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program |
| Q91672856 | Gendered and racialized social expectations, barriers, and delayed breast cancer diagnosis |
| Q22064616 | Genome-wide association studies and the clinic: a focus on breast cancer |
| Q30387719 | Getting clearer on overdiagnosis. |
| Q38596827 | Global cancer surgery: delivering safe, affordable, and timely cancer surgery. |
| Q38246653 | Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis |
| Q34327946 | How can polygenic inheritance be used in population screening for common diseases? |
| Q86253807 | IBIS-I tamoxifen update: maturity brings questions |
| Q36953954 | Identification of lesion subtypes in biopsies of ductal carcinoma in situ of the breast using biomarker ratio imaging microscopy |
| Q38331310 | Image toggling saves time in mammography |
| Q38950226 | Imaging and Histopathologic Features of BI-RADS 3 Lesions Upgraded during Imaging Surveillance |
| Q36366314 | Imaging-based screening: maximizing benefits and minimizing harms. |
| Q93270669 | Immune response and stromal changes in ductal carcinoma in situ of the breast are subtype dependent |
| Q57054843 | Impact of The Method of Diagnosis on The Stage of Breast Carcinoma |
| Q37119762 | Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence. |
| Q97535478 | Impact of mammographic screening and advanced cancer definition on the percentage of advanced-stage cancers in a steady-state breast screening programme in the Netherlands |
| Q47130704 | Implementation of shared decision-making in oncology: development and pilot study of a nurse-led decision-coaching programme for women with ductal carcinoma in situ. |
| Q55064947 | Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer. |
| Q26785575 | Implications of Overdiagnosis: Impact on Screening Mammography Practices |
| Q92665805 | Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014 |
| Q37001469 | Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program |
| Q55002227 | Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database. |
| Q90470630 | Increasing trends in in situ breast cancer incidence in a region with no population-based mammographic screening program: results from Zurich, Switzerland 2003-2014 |
| Q37258178 | Inequalities in socioeconomic status and race and the odds of undergoing a mammogram in Brazil |
| Q30987604 | Inference on cancer screening exam accuracy using population-level administrative data |
| Q37070417 | Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening |
| Q51033689 | Insights from the breast cancer screening trials: how screening affects the natural history of breast cancer and implications for evaluating service screening programs. |
| Q31111254 | Integration of Breast Cancer Secretomes with Clinical Data Elucidates Potential Serum Markers for Disease Detection, Diagnosis, and Prognosis |
| Q31120913 | Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer |
| Q58124814 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea |
| Q35672790 | Invasive Breast Cancer Incidence in 2,305,427 Screened Asymptomatic Women: Estimated Long Term Outcomes during Menopause Using a Systematic Review |
| Q38991248 | Investigation of gallic acid induced anticancer effect in human breast carcinoma MCF-7 cells. |
| Q91677426 | Irradiation induces p53 loss of heterozygosity in breast cancer expressing mutant p53 |
| Q30250289 | Is the false-positive rate in mammography in North America too high? |
| Q96297923 | LGR5 in breast cancer and ductal carcinoma in situ: a diagnostic and prognostic biomarker and a therapeutic target |
| Q88187265 | Lack of Impact of the 2009 USPSTF Guidelines on Rates of Mammography Screening |
| Q46315243 | Letter in response: breast cancer screening of women aged 70-74 years |
| Q57641629 | Lung cancer screening with low-dose computed tomography |
| Q92824703 | Malignant Pleural Effusion and Its Current Management: A Review |
| Q37422270 | Mammographic screening for breast cancer: Are the chickens coming home to roost? |
| Q89909084 | Mammography correlates to better survival rates in breast cancer patients: a 20-year experience in a University health institution |
| Q39302508 | Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014. |
| Q38083107 | Mammography for symptomless women--not so wise? |
| Q57415046 | Mammography screening and women with symptomatic breast cancer |
| Q35678672 | Mammography screening in three Finnish residential areas: comprehensive population-based study of breast cancer incidence and incidence-based mortality 1976-2009. |
| Q53349179 | Mammography screening is harmful and should be abandoned. |
| Q55556508 | Mammography to tomosynthesis: examining the differences between two-dimensional and segmented-three-dimensional visual search. |
| Q53667912 | Measurement of circulating cell-free DNA levels by a simple fluorescent test in patients with breast cancer. |
| Q36258422 | Medical Debates and Medical Reversal |
| Q47129780 | Metformin inhibits the development, and promotes the resensitization, of treatment-resistant breast cancer. |
| Q65001698 | Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored. |
| Q39022692 | Missteps in Current Estimates of Cancer Overdiagnosis |
| Q98158922 | Molecular Mechanisms Contributing Bacterial Infections to the Incidence of Various Types of Cancer |
| Q26748546 | Molecular biology of breast tumors and prognosis |
| Q53273557 | Molecular biology: Marked progress. |
| Q35002382 | Molecular breast imaging: an emerging modality for breast cancer screening |
| Q36039489 | Monocyte-derived macrophage assisted breast cancer cell invasion as a personalized, predictive metric to score metastatic risk. |
| Q37626915 | More misinformation on breast cancer screening |
| Q38802962 | Multivariate model to identify women at low risk of cancer upgrade after a core needle biopsy diagnosis of atypical ductal hyperplasia |
| Q38970049 | Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression |
| Q26864448 | Next-generation sequencing: a powerful tool for the discovery of molecular markers in breast ductal carcinoma in situ |
| Q35846869 | Non-normal Screening Mammography Results, Lumpectomies, and Breast Cancer Reported by California Women, 2001-2009. |
| Q48250080 | Nudging and the complicated real life of "informed consent". |
| Q96304710 | Omission of axillary lymph node dissection in patients who underwent total mastectomy with 1 or 2 metastatic lymph nodes |
| Q33872792 | Opportunistic Breast Cancer Education and Screening in Rural Honduras |
| Q36023456 | Opportunities for molecular epidemiological research on ductal carcinoma in-situ and breast carcinogenesis: interdisciplinary approaches |
| Q92708576 | Optimism may moderate screening mammogram frequency in Medicare: A longitudinal study |
| Q40363680 | Organization and Evaluation of Performance Indicators of a Breast Cancer Screening Program in Meknes-Tafilalt Region, Morocco |
| Q89127386 | Organized screening detects breast cancer at earlier stage regardless of molecular phenotype |
| Q54161798 | Overcalling low-risk findings: grouped amorphous calcifications found at screening mammography associated with minimal cancer risk. |
| Q37589081 | Overdiagnosing overdiagnosis |
| Q35072474 | Overdiagnosis in breast cancer chemoprevention trials |
| Q33691938 | Overdiagnosis in low-dose computed tomography screening for lung cancer |
| Q45924940 | Overdiagnosis of breast cancer. |
| Q35438645 | Overdiagnosis: epidemiologic concepts and estimation |
| Q37214228 | Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis |
| Q42323039 | Overestimating Overdiagnosis in Breast Cancer Screening |
| Q34071393 | Oversimplifying overdiagnosis |
| Q45063675 | Pan-Canadian study of mammography screening and mortality from breast cancer |
| Q40046269 | Paradigm Shift toward Reducing Overtreatment of Ductal Carcinoma In Situ of Breast |
| Q46350726 | Patient Navigation Improves Subsequent Breast Cancer Screening After a Noncancerous Result: Evidence from the Patient Navigation in Medically Underserved Areas Study |
| Q55262959 | Perceptions of overdetection of breast cancer among women 70 years of age and older in the USA: a mixed-methods analysis. |
| Q47361332 | Performance of 4 years of population-based mammography screening for breast cancer combined with ultrasound in Tyrol / Austria |
| Q35096373 | Perioperative dynamics and significance of amino acid profiles in patients with cancer |
| Q57453316 | Personalised medicine and population health: breast and ovarian cancer |
| Q35164227 | Perspectives on mammography after receipt of secondary screening owing to a false positive |
| Q89996784 | Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance) |
| Q30652392 | Phylogenetic analysis of multiprobe fluorescence in situ hybridization data from tumor cell populations |
| Q42369801 | Pitfalls in accurate estimation of overdiagnosis: implications for screening policy and compliance |
| Q60916645 | Plasma MicroRNA Pair Panels as Novel Biomarkers for Detection of Early Stage Breast Cancer |
| Q37243591 | Plasma exosome microRNAs are indicative of breast cancer |
| Q35032320 | Plasma microRNA panel for minimally invasive detection of breast cancer |
| Q89988188 | Plasma-based microRNA signatures in early diagnosis of breast cancer |
| Q92966277 | Polygenic risk-stratified screening for cancer: Responsibilization in public health genomics |
| Q64273148 | Population Screening for Cancer in High-Income Settings: Lessons for Low- and Middle-Income Economies |
| Q50055419 | Population impact of lung cancer screening in the United States: Projections from a microsimulation model. |
| Q30251601 | Population-based screening for cancer: hope and hype. |
| Q37593517 | Population-based service mammography screening: the Icelandic experience |
| Q38185110 | Position paper: breast cancer screening, diagnosis, and treatment in Denmark |
| Q34152757 | Potential overuse of screening mammography and its association with access to primary care |
| Q39620206 | Pre-Existing Diabetes in Early Stage Breast Cancer Patients is Associated with Lack of Improvement in Quality of Life 2 Years After Diagnosis |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q49188455 | Prediction of low-risk breast cancer using quantitative DCE-MRI and its pathological basis. |
| Q35879319 | Predictors of Non-Adherence to Breast Cancer Screening among Hospitalized Women |
| Q48166446 | Preliminary Results of a New Auxiliary Mechatronic Near-Field Radar System to 3D Mammography for Early Detection of Breast Cancer. |
| Q90341351 | Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer |
| Q47139917 | Prevalence of incidental breast cancer and precursor lesions in autopsy studies: a systematic review and meta-analysis |
| Q34354391 | Prevalence of mammographically dense breasts in the United States |
| Q27027277 | Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal |
| Q33691256 | Preventive health services implemented by family physicians in Portugal-a cross-sectional study based on two clinical scenarios |
| Q47552789 | Primary Care Provider Experience with Breast Density Legislation in Massachusetts |
| Q94554244 | Prognostic Factors of Disease Recurrence in Breast Cancer Using Quantitative and Qualitative Magnetic Resonance Imaging (MRI) Parameters |
| Q37389535 | Protocol for Biomarker Ratio Imaging Microscopy with Specific Application to Ductal Carcinoma In situ of the Breast |
| Q35694158 | Public health national approach to reducing breast and cervical cancer disparities |
| Q47631573 | Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology. |
| Q26824867 | Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods |
| Q47160671 | Quantitation of cell-free DNA in blood is a potential screening and diagnostic maker of breast cancer: a meta-analysis |
| Q94528674 | Racial Disparities in Cancer Presentation and Outcomes: The Contribution of Overdiagnosis |
| Q51780628 | Racial and ethnic disparities in the diagnosis of breast cancer: changes in presenting stage in minority populations in Florida during 1981-2009. |
| Q50598951 | Reaffirming normal: the high risk of pathologizing healthy adults when interpreting the MMPI-2-RF. |
| Q41588484 | Recent trends in adherence to continuous screening for breast cancer among Medicare beneficiaries |
| Q37353833 | Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them |
| Q37524981 | Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies |
| Q36962500 | Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention |
| Q51247171 | Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer. |
| Q92465996 | Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study |
| Q39077470 | Reoperation Rates in Ductal Carcinoma In Situ vs Invasive Breast Cancer After Wire-Guided Breast-Conserving Surgery |
| Q59334640 | Reply to flawed assumptions used to defend screening mammography |
| Q30252065 | Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening |
| Q36169940 | Response to: "Beyond the mammography debate: a moderate perspective". |
| Q36755186 | Results of the national lung cancer screening trial: where are we now? |
| Q36198266 | Retrospective observation on contribution and limitations of screening for breast cancer with mammography in Korea: detection rate of breast cancer and incidence rate of interval cancer of the breast |
| Q92875395 | Review and Comparison of Cancer Biomarker Trends in Urine as a Basis for New Diagnostic Pathways |
| Q38672973 | Reviewing risks and benefits of low-dose computed tomography screening for lung cancer |
| Q51313302 | Revised estimates of overdiagnosis from the Canadian National Breast Screening Study. |
| Q36000373 | Risks of developing breast and colorectal cancer in association with incomes and geographic locations in Texas: a retrospective cohort study. |
| Q40645063 | SERS analysis of serum for detection of early and locally advanced breast cancer |
| Q33594853 | SMARCE1 is required for the invasive progression of in situ cancers |
| Q36404777 | Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study |
| Q40949000 | Screening Mammography Rates in the Medicare Population before and after the 2009 U.S. Preventive Services Task Force Guideline Change: An Interrupted Time Series Analysis |
| Q39592114 | Screening Mammography Use Among Older Women Before and After the 2009 U.S. Preventive Services Task Force Recommendations |
| Q42067852 | Screening Mammography: A Pilot Study on Its Pertinence in Indian Population by Means of a Camp. |
| Q47434341 | Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer |
| Q55396634 | Screening for breast cancer in 2018-what should we be doing today? |
| Q24202273 | Screening for breast cancer with mammography |
| Q27021899 | Screening guidelines for non-AIDS defining cancers in HIV-infected individuals |
| Q89012840 | Screening mammography among nursing home residents in the United States: Current guidelines and practice |
| Q26829839 | Screening mammography in older women: a review |
| Q39130369 | Screening mammography may be less effective than thought |
| Q30851278 | Screening mammography--early detection or over-diagnosis? Contribution from Australian data |
| Q37373148 | Screening mammography: sparing the emperor's blushes |
| Q40308627 | Screening: Don't look now. |
| Q87172991 | Secular trends, race, and geographic disparity of early-stage breast cancer incidence: 25 years of surveillance in Connecticut |
| Q88938382 | Should we expect all-cause mortality reductions in large screening studies? |
| Q51778588 | Social network effects of nonlifesaving early-stage breast cancer detection on mammography rates. |
| Q26738275 | Spatial Genome Organization and Its Emerging Role as a Potential Diagnosis Tool |
| Q35929078 | Stage of breast cancer at diagnosis in New Zealand: impacts of socio-demographic factors, breast cancer screening and biology |
| Q51578587 | Statistical analyses in Swedish randomised trials on mammography screening and in other randomised trials on cancer screening: a systematic review. |
| Q38150222 | Suitable trial designs and cohorts for preventive breast cancer agents |
| Q50051709 | Survival analysis of women with breast cancer: competing risk models. |
| Q38126067 | Systematic review about breast cancer incidence in relation to hormone replacement therapy use. |
| Q36183280 | Temporal trends in the risk of developing multiple primary cancers: a systematic review. |
| Q30357555 | Testing a dual-modality system that combines full-field digital mammography and automated breast ultrasound. |
| Q45825533 | The 20-year effort to reduce access to mammography screening: historical facts dispute a commentary in Cancer |
| Q38154495 | The 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: MRI in breast cancer: where are we now? |
| Q96304637 | The Burden and Trends of Breast Cancer From 1990 to 2017 at the Global, Regional, and National Levels: Results From the Global Burden of Disease Study 2017 |
| Q30837583 | The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis |
| Q37708613 | The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model |
| Q58612576 | The Evolution of Mammography Controversy in the News Media: A Content Analysis of Four Publicized Screening Recommendations, 2009 to 2016 |
| Q34887066 | The Hundred Person Wellness Project and Google's Baseline Study: medical revolution or unnecessary and potentially harmful over-testing? |
| Q38840507 | The Japanese Guidelines for Breast Cancer Screening |
| Q43128206 | The Marmot report: accepting the poisoned chalice |
| Q47233390 | The Medicalization of Health and Shared Responsibility |
| Q38687682 | The Population Burden of Cancer: Research Driven by the Catchment Area of a Cancer Center |
| Q37153116 | The Role of Intraoperative Pathologic Assessment in the Surgical Management of Ductal Carcinoma In Situ |
| Q58801275 | The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI |
| Q87398015 | The association between cervical cancer screening and mortality from cervical cancer: a population based case-control study |
| Q27347267 | The contribution of mammography screening to breast cancer incidence trends in the United States: an updated age-period-cohort model |
| Q37301468 | The global challenge of reducing breast cancer mortality |
| Q28388257 | The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis |
| Q57106434 | The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review |
| Q89973371 | The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review |
| Q90123045 | The incidence of breast cancer in Canada 1971-2015: trends in screening-eligible and young-onset age groups |
| Q35037251 | The potential of hypoxia markers as target for breast molecular imaging--a systematic review and meta-analysis of human marker expression |
| Q42969064 | The risks of information in health care: do we need a new decision aid? |
| Q37154225 | The wizard behind the curtain: programmers as providers |
| Q52838790 | Three-dimensional reconstruction of ductal carcinoma in situ with virtual slides. |
| Q41675084 | Thyroid cancer incidence attributable to overdiagnosis in the United States 1981-2011. |
| Q39703687 | Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. |
| Q49974571 | Towards more effective online information support for mammography screening decisions. |
| Q30244636 | Treatment of low-risk ductal carcinoma in situ: is nothing better than something? |
| Q34243127 | Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage |
| Q60920138 | Trends in Breast Cancer Incidence and Stage Distribution Before and During the Introduction of the Mammography Screening Program in Lithuania |
| Q92003960 | Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers |
| Q36447987 | Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ |
| Q46588380 | Trends in aggregate cancer incidence rates in relation to screening and possible overdiagnosis: a word of caution |
| Q38094973 | Trends in breast cancer incidence and mortality in the United States: implications for prevention |
| Q38421948 | Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway |
| Q58803134 | Trends in incidence, mortality and survival in women with breast cancer from 1985 to 2012 in Granada, Spain: a population-based study |
| Q50190726 | Trends in mammography screening rates after publication of the 2009 US Preventive Services Task Force recommendations. |
| Q40077849 | Trends in stage-specific breast cancer incidence in New South Wales, Australia: insights into the effects of 25 years of screening mammography |
| Q47611129 | Trends in the clinical stage distribution of breast cancer in Osaka, Japan |
| Q30401159 | Truth or Spin? Disease Definition in Cancer Screening |
| Q38873275 | Tumor apparent diffusion coefficient as an imaging biomarker to predict tumor aggressiveness in patients with estrogen-receptor-positive breast cancer |
| Q49789105 | Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes? |
| Q34425577 | Tumour cell invasion: an emerging role for basal epithelial cell extrusion |
| Q34403715 | Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial |
| Q52573652 | Uncertain times: A survey of Canadian women's perspectives toward mammography screening. |
| Q47560059 | Understanding and misunderstanding randomized controlled trials |
| Q34075267 | Update on new technologies in digital mammography |
| Q47647467 | Urban/Rural Differences in Breast and Cervical Cancer Incidence: The Mediating Roles of Socioeconomic Status and Provider Density |
| Q64115107 | Use of Mastectomy for Overdiagnosed Breast Cancer in the United States: Analysis of the SEER 9 Cancer Registries |
| Q34037876 | Use of autoantibodies to detect the onset of breast cancer |
| Q92397334 | Using Public Claims Data for Neighborhood Level Epidemiologie Surveillance of Breast Cancer Screening: Findings from Evaluating a Patient Navigation Program in Chicago's Chinatown |
| Q36823230 | Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs |
| Q64085883 | Utilisation of mammography by women with mobility impairment in the UK: secondary analysis of cross-sectional data |
| Q27001399 | Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel |
| Q41492226 | Validation of the 18-gene classifier as a prognostic biomarker of distant metastasis in breast cancer. |
| Q37340649 | Variability in Pathologists' Interpretations of Individual Breast Biopsy Slides: A Population Perspective |
| Q40877930 | Vegetarianism, low meat consumption and the risk of lung, postmenopausal breast and prostate cancer in a population-based cohort study |
| Q48194073 | Verification of recall criteria for masses detected on ultrasound breast cancer screening. |
| Q38537197 | Viewpoint: It is time to reconsider policy for population-based mammography screening |
| Q33623142 | WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells |
| Q37589078 | Were our estimates of overdiagnosis with mammography screening in the United States "based on faulty science"? |
| Q57723663 | What Explains Education Disparities in Screening Mammography in the United States? A Comparison with The Netherlands |
| Q37719693 | What are our Options in the Fight against Breast Cancer? |
| Q45867222 | What's a girl to do? |
| Q36980173 | Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention |
| Q40848203 | Who does not get screened? A simple model of the complex relationships in mammogram non-attendance |
| Q35922603 | Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women. |
| Q92973962 | Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease? |
| Q40723108 | Why reconsider the recommendation of breast cancer screening? |
| Q35105050 | Willingness to participate in mammography screening: a randomized controlled questionnaire study of responses to two patient information leaflets with different factual content |
| Q36452292 | Women's Expectations for Breast Cancer Prevention and Early Detection: High Expectations Can Be Achieved |
| Q35065272 | Women's responses to changes in U.S. Preventive Task Force's mammography screening guidelines: results of focus groups with ethnically diverse women |
| Q30532790 | Women's views on overdiagnosis in breast cancer screening: a qualitative study |
| Q39537247 | Worse Breast Cancer Outcomes for Southern Nevadans, Filipina and Black Women. |
| Q90528546 | [Image-based screening] |
| Q53808551 | [Is Grail's goal feasible?]. |
| Q92461147 | miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2 |
Search more.